skip to Main Content

Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.

Colunga A, Pulliam T, Nghiem P.

Clin Cancer Res. 2018 May 1;24(9):2035-2043.

PMID: 29217527

View on PubMed - View PDF

Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients.

Tarabadkar ES, Thomas H, Blom A, Parvathaneni U, Olencki T, Nghiem P, Bhatia S.

Am J Case Rep 2018; 19:505-511

PMID: 29706615

View on PubMed - View PDF

Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.

Becker JC, Stang A, zur Hausen A, Fischer N, DeCaprio JA, Tothill RW, Lyngaa R, Hansen UK, Ritter C, Nghiem P, Bichakjian CK, Ugurel S, Schrama D.

Cancer Immunol Immunother. 2018 Mar;67(3):341-351.

PMID: 29188306

View on PubMed - View PDF

Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics.

Paulson KG, Park SY, Vandeven NA, Lachance K, Thomas H, Chapuis AG, Harms KL, Thompson JA, Bhatia S, Stang A, Nghiem P.

J Am Acad Dermatol. 2018 Mar;78(3):457-463.

PMID: 29102486

View on PubMed - View PDF

Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival.

Vandeven N, Lewis CW, Makarov V, Riaz N, Paulson KG, Hippe D, Bestick A, Doumani R, Marx T, Takagishi S, Chan TA, Choi J, Nghiem P.

Clin Cancer Res. 2018 Feb 15;24(4):963-971.

PMID: 29246939

View on PubMed - View PDF

Updated efficacy of avelumab in patients with previously treate metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trail.

Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, Shih KC, Lebbé C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P.

J Immunother Cancer. 2018 Jan 19;6(1):7.

PMID: 29347993

View on PubMed - View PDF


Merkel Cell Carcinoma

Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, Nghiem P

Nat Rev Dis Primers. 2017 Oct 26;3:17077.

PMID: 29072302

View on PubMed - View PDF

CD200 Expression in Neuroendocrine Neoplasms.

Love JE, Thompson K, Kilgore MR, Westerhoff M, Murphy CE, Papanicolau-Sengos A, McCormick KA, Shankaran V, Vandeven N, Miller F, Blom A, Nghiem PT, Kussick SJ.

Am J Clin Pathol. 2017 Sep 1;148(3):236-242.

PMID: 28821198

View on PubMed - View PDF

Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.

Schadendorf D, Nghiem P, Bhatia S, Hauschild A, Saiag P, Mahnke L, Hariharan S, Kaufman HL.

Oncoimmunology. 2017 Aug 31;6(10):e1338237.

PMID: 29123950

View on PubMed - View PDF

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.

Nghiem P, Kaufman HL, Bharmal M, Mahnke L, Phatak H, Becker JC.

Future Oncol. 2017 Jun;13(14):1263-1279.

PMID: 28350180

View on PubMed - View PDF

Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.

Ritter C, Fan K, Paschen A, Reker S, Ferrone S, Nghiem P, Ugurel S, Schrama D, Becker JC.

Sci Rep. 2017 May 23;7(1):2290.

PMID: 28536458

View on PubMed - View PDF

Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study.

Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, Morishima C, Hutchinson K, Mudgistratova L, Blom A, Iyer J, Moshiri AS, Tarabadkar ES, Carter JJ, Bhatia S, Kawasumi M, Galloway DA, Wener MH, Nghiem P.

Cancer. 2017 Apr 15;123(8):1464-1474.

PMID: 27925665

View on PubMed - View PDF

Back To Top